Εμφάνιση απλής εγγραφής

dc.creatorKoutalos A.A., Stefanou N., Malizos K.N.en
dc.date.accessioned2023-01-31T08:45:56Z
dc.date.available2023-01-31T08:45:56Z
dc.date.issued2022
dc.identifier10.1016/j.ijid.2022.04.026
dc.identifier.issn12019712
dc.identifier.urihttp://hdl.handle.net/11615/75370
dc.description.abstractRecovery from COVID-19 is not always uneventful, especially in critically ill hospitalized patients. Persistent symptoms including fatigue/ weakness, shortness of breath, anxiety, and depression have been described at one-year follow-up. Furthermore, symptoms from the musculoskeletal system like joint pain or stiffness are underreported in studies with long-term follow-up of up to one year. Infection with SARS-CoV-2 itself has been associated with endothelial damage, and together with high-dose corticosteroid treatment, it is predisposed to the dissemination of microthrombi and the development of femoral head osteonecrosis (FHOn), as it has been shown during the previous (2003–2004) coronavirus outbreaks. A resurgence of FHOn cases is anticipated but this is not reflected in the existing studies with long-term follow-up. Prompt diagnosis is critical for early treatment and possibly for the hip joint preservation. Patients with COVID-19 treated with corticosteroids should be screened for avascular necrosis early after discharge from the hospital. Every healthcare worker involved in the management of these patients should maintain a high level of suspicion and should be alert when patients report symptoms such as vague aches at the buttocks, hip area, adductors, and/or above the knee. Studies are needed to identify risk factors for FHOn including disease severity, type of steroid, cumulative dose, and duration of treatment. © 2022en
dc.language.isoenen
dc.sourceInternational Journal of Infectious Diseasesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85129946570&doi=10.1016%2fj.ijid.2022.04.026&partnerID=40&md5=d441512c34b0a0fc568767190b09cdf4
dc.subjectcorticosteroiden
dc.subjectlopinaviren
dc.subjectprednisoloneen
dc.subjectritonaviren
dc.subjectcorticosteroiden
dc.subjectall cause mortalityen
dc.subjectanxietyen
dc.subjectarthralgiaen
dc.subjectavascular necrosisen
dc.subjectbone necrosisen
dc.subjectcoronavirus disease 2019en
dc.subjectcritically ill patienten
dc.subjectdepressionen
dc.subjectdisease associationen
dc.subjectdisease courseen
dc.subjectdisease durationen
dc.subjectdisease severityen
dc.subjectdrug megadoseen
dc.subjectdyspneaen
dc.subjectfatigueen
dc.subjectfemur head necrosisen
dc.subjectfollow upen
dc.subjecthealth care personnelen
dc.subjecthip painen
dc.subjecthospital dischargeen
dc.subjecthospital patienten
dc.subjecthumanen
dc.subjectincidenceen
dc.subjectjoint stiffnessen
dc.subjectmuscle weaknessen
dc.subjectpandemicen
dc.subjectquality of lifeen
dc.subjectrisk factoren
dc.subjectShort Surveyen
dc.subjecttotal hip replacementen
dc.subjecttreatment durationen
dc.subjectbone necrosisen
dc.subjectcomplicationen
dc.subjectdisease exacerbationen
dc.subjectepidemicen
dc.subjectseverity of illness indexen
dc.subjectAdrenal Cortex Hormonesen
dc.subjectCOVID-19en
dc.subjectDisease Outbreaksen
dc.subjectDisease Progressionen
dc.subjectHumansen
dc.subjectOsteonecrosisen
dc.subjectSARS-CoV-2en
dc.subjectSeverity of Illness Indexen
dc.subjectElsevier B.V.en
dc.titlePostacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlookeden
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής